These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15922837)

  • 1. Synthesis and evaluation of double bond substituted combretastatins.
    Hadfield JA; Gaukroger K; Hirst N; Weston AP; Lawrence NJ; McGown AT
    Eur J Med Chem; 2005 Jun; 40(6):529-41. PubMed ID: 15922837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural requirements for the interaction of combretastatins with tubulin: how important is the trimethoxy unit?
    Gaukroger K; Hadfield JA; Lawrence NJ; Nolan S; McGown AT
    Org Biomol Chem; 2003 Sep; 1(17):3033-7. PubMed ID: 14518125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combretastatin dinitrogen-substituted stilbene analogues as tubulin-binding and vascular-disrupting agents.
    Siles R; Ackley JF; Hadimani MB; Hall JJ; Mugabe BE; Guddneppanavar R; Monk KA; Chapuis JC; Pettit GR; Chaplin DJ; Edvardsen K; Trawick ML; Garner CM; Pinney KG
    J Nat Prod; 2008 Mar; 71(3):313-20. PubMed ID: 18303849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological activity of mustard derivatives of combretastatins.
    Coggiola B; Pagliai F; Allegrone G; Genazzani AA; Tron GC
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3551-4. PubMed ID: 15963722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New naphthylcombretastatins. Modifications on the ethylene bridge.
    Sánchez Maya AB; Pérez-Melero C; Salvador N; Peláez R; Caballero E; Medarde M
    Bioorg Med Chem; 2005 Mar; 13(6):2097-107. PubMed ID: 15727863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel cyanocombretastatins as potent tubulin polymerisation inhibitors.
    Jalily PH; Hadfield JA; Hirst N; Rossington SB
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6731-4. PubMed ID: 23010271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and cytotoxic evaluation of combretafurans, potential scaffolds for dual-action antitumoral agents.
    Pirali T; Busacca S; Beltrami L; Imovilli D; Pagliai F; Miglio G; Massarotti A; Verotta L; Tron GC; Sorba G; Genazzani AA
    J Med Chem; 2006 Aug; 49(17):5372-6. PubMed ID: 16913727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, biochemical, and biological evaluation of nitrogen-containing trifluoro structural modifications of combretastatin A-4.
    Hall JJ; Sriram M; Strecker TE; Tidmore JK; Jelinek CJ; Kumar GD; Hadimani MB; Pettit GR; Chaplin DJ; Trawick ML; Pinney KG
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5146-9. PubMed ID: 18710804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and antimicrotubule activity of combretatropone derivatives.
    Janik ME; Bane SL
    Bioorg Med Chem; 2002 Jun; 10(6):1895-903. PubMed ID: 11937347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological activity of naphthalene analogues of phenstatins: naphthylphenstatins.
    Alvarez C; Alvarez R; Corchete P; Pérez-Melero C; Peláez R; Medarde M
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3417-20. PubMed ID: 17434303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrazolone-fused combretastatins and their precursors: synthesis, cytotoxicity, antitubulin activity and molecular modeling studies.
    Burja B; Cimbora-Zovko T; Tomić S; Jelusić T; Kocevar M; Polanc S; Osmak M
    Bioorg Med Chem; 2010 Apr; 18(7):2375-87. PubMed ID: 20338766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regioselective Suzuki coupling of dihaloheteroaromatic compounds as a rapid strategy to synthesize potent rigid combretastatin analogues.
    Theeramunkong S; Caldarelli A; Massarotti A; Aprile S; Caprioglio D; Zaninetti R; Teruggi A; Pirali T; Grosa G; Tron GC; Genazzani AA
    J Med Chem; 2011 Jul; 54(14):4977-86. PubMed ID: 21696175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological activity of fluorinated combretastatin analogues.
    Alloatti D; Giannini G; Cabri W; Lustrati I; Marzi M; Ciacci A; Gallo G; Tinti MO; Marcellini M; Riccioni T; Guglielmi MB; Carminati P; Pisano C
    J Med Chem; 2008 May; 51(9):2708-21. PubMed ID: 18396857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of azaisoerianin derivatives as potential antitumors agents.
    Soussi MA; Provot O; Bernadat G; Bignon J; Wdzieczak-Bakala J; Desravines D; Dubois J; Brion JD; Messaoudi S; Alami M
    Eur J Med Chem; 2014 May; 78():178-89. PubMed ID: 24681982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p,p-Dihydroxydihydrostilbenophanes related to antimitotic combretastatins. Conformational analysis and its relationship to tubulin inhibition.
    Álvarez R; López V; Mateo C; Medarde M; Peláez R
    J Org Chem; 2014 Aug; 79(15):6840-57. PubMed ID: 24966024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity.
    Ducki S; Rennison D; Woo M; Kendall A; Chabert JF; McGown AT; Lawrence NJ
    Bioorg Med Chem; 2009 Nov; 17(22):7698-710. PubMed ID: 19837593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformationally restricted macrocyclic analogues of combretastatins.
    Mateo C; Alvarez R; Pérez-Melero C; Peláez R; Medarde M
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6316-20. PubMed ID: 17889536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of dihydronaphthalene and benzosuberene analogs of the combretastatins as inhibitors of tubulin polymerization in cancer chemotherapy.
    Sriram M; Hall JJ; Grohmann NC; Strecker TE; Wootton T; Franken A; Trawick ML; Pinney KG
    Bioorg Med Chem; 2008 Sep; 16(17):8161-71. PubMed ID: 18722127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of combretastatin nitrogen-containing derivatives as inhibitors of tubulin assembly and vascular disrupting agents.
    Monk KA; Siles R; Hadimani MB; Mugabe BE; Ackley JF; Studerus SW; Edvardsen K; Trawick ML; Garner CM; Rhodes MR; Pettit GR; Pinney KG
    Bioorg Med Chem; 2006 May; 14(9):3231-44. PubMed ID: 16442292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical design of antimitotic agents based on combretastatins.
    Hsieh HP; Liou JP; Mahindroo N
    Curr Pharm Des; 2005; 11(13):1655-77. PubMed ID: 15892667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.